Glucagon/GLP-1 receptor co-agonists
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
1. A pegylated glucagon peptide of the following structure:
wherein “Peptide” comprises the following sequence:
(SEQ ID NO: 588)
X1SQGT FTSDY SKYLD ERRAK DFVC*W LMNTa
wherein:
“X1” is alpha, alpha-dimethyl imidazole acetic acid;
“C*” is a Cysteine residue on the glucagon peptide having a thiol which is connected to a polyethylene glycol of about 20 kD or about 40 kD average weight;
“a” is a C-terminal amide; and
further wherein there is a lactam bridge between amino acids 16 and 20 of the Peptide;
or a pharmaceutically acceptable salt thereof.
2. The peptide of claim 1 , wherein the polyethylene glycol is about 40 kD average weight.
3. A pharmaceutical composition comprising the glucagon peptide of claim 1 or 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. A method of treating hyperglycemia, said method comprising the step of administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 3 .
5. A method of treating diabetes, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 3 .
6. A method of reducing weight gain or inducing weight loss, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 3 .
7. A pegylated glucagon peptide of the following structure:
wherein “Peptide” comprises the following sequence:
(SEQ ID NO: 319)
HX2EGT FTSDY SKYLD EQAAK EFIC*W LMNTa
wherein:
“X2” is aminoisobutyric acid;
“C*” is a Cysteine residue on the glucagon peptide having a thiol which is connected to a polyethylene glycol of about 20 kD or about 40 kD average weight; and
“a” is a C-terminal amide;
or a pharmaceutically acceptable salt thereof.
8. The pegylated glucagon peptide of claim 7 , wherein the polyethylene glycol is about 40 kD average weight.
9. A pharmaceutical composition comprising the glucagon peptide of claim 7 or 8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
10. A method of treating hyperglycemia, said method comprising the step of administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 9 .
11. A method of treating diabetes, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 9 .
12. A method of reducing weight gain or inducing weight loss, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 9 .